Loading…
Akums Drugs and Pharmaceuticals (AKUMS)₹765.85+2.96%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Akums Drugs and Pharmaceuticals reported sales of ₹1,165 Cr, up 14.0% from Jun 2025, and net profit of ₹101 Cr, up 55.5% year on year. For the year to Mar 2026, sales were ₹4,347 Cr and net profit ₹255 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,177 | 1,081 | 941 | 1,016 | 1,031 | 1,008 | 1,053 | 1,021 | 1,016 | 1,158 | 1,155 | 1,165 |
| Expenses | 1,026 | 986 | 939 | 888 | 909 | 886 | 958 | 893 | 921 | 1,010 | 1,003 | 989 |
| Operating Profit | 152 | 93.28 | 3.01 | 128 | 121 | 121 | 94.36 | 129 | 94.40 | 148 | 152 | 176 |
| OPM % | 13.0% | 9.0% | 0.3% | 13.0% | 12.0% | 12.0% | 9.0% | 13.0% | 9.0% | 12.9% | 13.0% | 15.0% |
| Other Income | −21.01 | 10.01 | 10.01 | 7.01 | 17.02 | 19.02 | 26.02 | 27.01 | 32.03 | 16.01 | 34.03 | 30.04 |
| Interest | 14.01 | 12.02 | 12.02 | 13.02 | 12.02 | 5.01 | 5.01 | 23.04 | 23.04 | 24.05 | 24.02 | 25.03 |
| Depreciation | 29.98 | 32.01 | 33.99 | 34.01 | 34.99 | 44.94 | 39.96 | 37.01 | 38.01 | 39.96 | 39.95 | 40.98 |
| Profit before tax | 86.74 | 58.86 | −32.91 | 86.77 | 91.70 | 90.71 | 74.75 | 95.76 | 65.85 | 99.76 | 121 | 139 |
| Tax % | 61.9% | −229.1% | 20.0% | 30.0% | 27.0% | 27.0% | −99.1% | 32.0% | 35.0% | 32.0% | 33.0% | 26.9% |
| Exceptional items | −9.96 | 0.99 | 0.00 | 0.00 | 2.99 | 2.99 | 5.98 | 0.00 | 0.00 | −11.95 | −0.99 | 0.00 |
| Net Profit | 32.88 | 194 | −38.89 | 60.80 | 66.80 | 65.84 | 150 | 64.77 | 42.83 | 67.79 | 80.73 | 101 |
| EPS (Rs) | 2.23 | 13.55 | −2.90 | 4.09 | 4.13 | 4.15 | 9.39 | 4.04 | 2.60 | 4.22 | 5.39 | 6.36 |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,461 | 1,647 | 2,409 | 2,717 | 3,661 | 3,648 | 4,165 | 4,104 | 4,347 | 4,493 |
| Expenses | 1,336 | 1,502 | 2,232 | 2,477 | 3,751 | 3,349 | 4,045 | 3,641 | 3,826 | 3,923 |
| Operating Profit | 124 | 145 | 175 | 239 | −89.34 | 295 | 123 | 467 | 524 | 570 |
| OPM % | 8.0% | 9.0% | 7.0% | 9.0% | −2.4% | 8.0% | 3.0% | 11.0% | 12.0% | 12.7% |
| Other Income | 6.01 | 6.01 | 26.01 | 10.99 | 6.99 | 15.01 | 8.01 | 69.05 | 108 | 112 |
| Interest | 23.03 | 22.02 | 20.03 | 7.01 | 17.01 | 46.06 | 51.07 | 35.05 | 94.06 | 96.14 |
| Depreciation | 30.97 | 37.98 | 66.97 | 69.91 | 95.01 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 76.79 | 88.78 | 114 | 172 | −192 | 149 | −44.88 | 344 | 381 | 425 |
| Tax % | 51.0% | 50.0% | 62.0% | 27.9% | 30.0% | 34.9% | −102.1% | 0.0% | 33.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | −6.98 | −8.97 | −31.87 | 16.93 | 15.94 | −12.95 | −12.94 |
| Net Profit | 42.84 | 60.83 | 43.85 | 123 | −250 | 97.71 | 0.99 | 343 | 255 | 292 |
| EPS (Rs) | 366.68 | 523.54 | 335.95 | 943.93 | −35.29 | 6.64 | −0.29 | 21.50 | 16.22 | 18.57 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 18.1% | — |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.99 | 1.01 | 0.99 | 0.99 | 13.98 | 29.01 | 28.99 | 30.98 | 30.96 |
| Reserves | 493 | 628 | 720 | 883 | 608 | 688 | 681 | 3,016 | 3,279 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88.07 | 157 |
| Other Liabilities | 294 | 320 | 1,144 | 1,139 | 2,038 | 1,911 | 2,235 | 965 | 1,967 |
| Total Liabilities | 1,043 | 1,163 | 2,040 | 2,154 | 3,055 | 3,246 | 3,509 | 4,099 | 5,434 |
| Fixed Assets | 445 | 503 | 646 | 906 | 1,024 | 1,100 | 1,194 | 1,401 | 1,459 |
| CWIP | 0.00 | 11.01 | 57.04 | 17.01 | 31.05 | 103 | 195 | 163 | 177 |
| Investments | 0.00 | 17.97 | 5.99 | 19.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 598 | 633 | 1,331 | 1,212 | 2,000 | 2,043 | 2,120 | 2,535 | 3,798 |
| Inventories | 261 | 289 | 398 | 430 | 722 | 730 | 630 | 681 | 756 |
| Trade receivables | 272 | 258 | 580 | 529 | 881 | 842 | 831 | 767 | 794 |
| Cash & equivalents | 12.02 | 14.02 | 147 | 68.18 | 103 | 150 | 278 | 577 | 1,685 |
| Total Assets | 1,043 | 1,163 | 2,040 | 2,154 | 3,055 | 3,246 | 3,509 | 4,099 | 5,434 |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 71.89 | 88.94 | 27.99 | 131 | 31.99 | 177 | 498 | 465 | 1,180 |
| Cash from investing activity | −150 | −123 | −190 | −109 | −234 | −304 | −330 | −547 | −927 |
| Cash from financing activity | 65.79 | 36.84 | 232 | −90.59 | 235 | 125 | −108 | 72.71 | 33.84 |
| Net cash flow | −11.03 | 4.01 | 71.15 | −70.21 | 33.08 | −4.01 | 59.18 | −10.03 | 286 |
| Capex | 150 | 125 | 61.90 | 82.89 | 258 | 329 | 310 | 272 | 231 |
| Free cash flow | −78.07 | −34.02 | −34.06 | 49.04 | −224 | −110 | 212 | 201 | 959 |
| CFO / OP % | 72.0% | 98.1% | 44.1% | 74.0% | −98.0% | 93.0% | 455.0% | 118.1% | 243.0% |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 69 | 58 | 89 | 72 | 89 | 85 | 74 | 69 | 68 |
| Inventory days | 115 | 116 | 100 | 94 | 113 | 118 | 91 | 103 | 111 |
| Days payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash conversion cycle | 116 | 113 | 83 | 91 | 110 | 112 | 88 | 75 | 90 |
| Working capital days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
| ROCE % | — | 14.0% | — | 20.0% | −16.0% | 22.0% | 2.0% | 16.0% | 15.0% |
For the Jun 2026 quarter, Akums Drugs and Pharmaceuticals reported sales of ₹1,165 Cr, up 14.0% year on year and net profit of ₹101 Cr, up 55.5% year on year. The operating margin was 15.0%.
Akums Drugs and Pharmaceuticals' sales for the year to Mar 2026 were ₹4,347 Cr; over the last twelve months they were ₹4,493 Cr.
Net profit for the year to Mar 2026 was ₹255 Cr, and ₹292 Cr over the last twelve months. Earnings per share over the same trailing period were ₹18.57.
Akums Drugs and Pharmaceuticals reported borrowings of ₹157 Cr at Mar 2026, against cash and equivalents of ₹1,685 Cr.
Cash from operations was ₹1,180 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹959 Cr.